BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
일요일, 9월 27

Arrowhead Pharmaceuticals Inc

ARWRNASDAQ
Trade with Public
Trade with Public
$65.92
-0.15-0.23%
가까이에: Sep 25, 5:00 PM EST
$65.70
-0.22-0.33%
시간외: Sep 25, 6:00 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Arrowhead Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Arrowhead Pharma (ARWR).

Price Target Range — 12 Quarters

Analyst Consensus — 14 Analysts

11Buy
3Hold
Consensus RatingBuy# Analysts14Avg. Consensus PT$88Upside to Avg. PT+34.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Sep 24, 2026Goldman SachsAndrea NewkirkReinstatesNeutral$74
Sep 8, 2026CitigroupEric JosephInitiateBuy$108
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Goldman Sachs Reinstates Neutral on Arrowhead Pharma, Announces $74 Price Target

Goldman Sachs analyst Andrea Newkirk reinstates Arrowhead Pharma (NASDAQ:ARWR) with a Neutral and announces $74 price target.
Benzinga Newsdesk

PRO
Citigroup Initiates Coverage On Arrowhead Pharma with Buy Rating, Announces Price Target of $108

Citigroup analyst Eric Joseph initiates coverage on Arrowhead Pharma (NASDAQ:ARWR) with a Buy rating and announces Price Target of $108.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $120 price target.
Benzinga Newsdesk

PRO
RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $100 Price Target

RBC Capital analyst Luca Issi reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Outperform and maintains $100 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $120

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises the price target from $115 to $120.
Benzinga Newsdesk

PRO
B. Riley Securities Maintains Buy on Arrowhead Pharma, Raises Price Target to $123

B. Riley Securities analyst Madison El-Saadi maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises the price target from $101 to $123.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved